tbuckley/cabot-search huggingface dataset:
Angiopoietin-2–Dependent Spatial Vascular Destabilization Promotes T-cell Exclusion and Limits Immunotherapy in Melanoma
Authors: Ha-Ram Park, Anahita Shiva, Portia Cummings, Seoyeon Kim, Sungsoo Kim, Eunhyeong Lee, Alessandra Leong, Subrata Chowdhury, Carrie Shawber, Richard Carvajal, Gavin Thurston, Joon-Yong An, Amanda W. Lund, Hee Won Yang, Minah Kim
Journal: Cancer Research (2023)

Abstract T-cell position in the tumor microenvironment determines the probability of target encounter and tumor killing. CD8+ T-cell exclusion from the tumor parenchyma is associated with poor response to immunotherapy, and yet the biology that underpins this distinct pattern remains unclear. Here we show that the vascular destabilizing factor angiopoietin-2 (ANGPT2) causes compromised vascular integrity in the tumor periphery, leading to impaired T-cell infiltration to the tumor core. The spatial regulation of ANGPT2 in whole tumor cross-sections was analyzed in conjunction with T-cell distribution, vascular integrity, and response to immunotherapy in syngeneic murine melanoma models. T-cell exclusion was associated with ANGPT2 upregulation and elevated vascular leakage at the periphery of human and murine melanomas. Both pharmacologic and genetic blockade of ANGPT2 promoted CD8+ T-cell infiltration into the tumor core, exerting antitumor effects. Importantly, the reversal of T-cell exclusion following ANGPT2 blockade not only enhanced response to anti-PD-1 immune checkpoint blockade therapy in immunogenic, therapy-responsive mouse melanomas, but it also rendered nonresponsive tumors susceptible to immunotherapy. Therapeutic response after ANGPT2 blockade, driven by improved CD8+ T-cell infiltration to the tumor core, coincided with spatial TIE2 signaling activation and increased vascular integrity at the tumor periphery where endothelial expression of adhesion molecules was reduced. These data highlight ANGPT2/TIE2 signaling as a key mediator of T-cell exclusion and a promising target to potentiate immune checkpoint blockade efficacy in melanoma. Significance: ANGPT2 limits the efficacy of immunotherapy by inducing vascular destabilization at the tumor periphery to promote T-cell exclusion.
Dynamic Contrast-enhanced MRI Demonstrates Pulmonary Microvascular Abnormalities Months After SARS-CoV-2 Infection
Authors: Iris Y. Zhou, Molly Mascia, George A. Alba, Michael Magaletta, Leo C. Ginns, Peter Caravan, Sydney B. Montesi
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Dynamic Contrast-Enhanced MRI Demonstrates Pulmonary Microvascular Abnormalities Months After SARS-CoV-2 Infection ." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Transcription factor Nkx2-3 maintains the self-renewal of hematopoietic stem cells by regulating mitophagy
Authors: Mengjia Hu, Naicheng Chen, Mo Chen, Fang Chen, Yukai Lu, Yang Xu, Lijing Yang, Hao Zeng, Mingqiang Shen, Xuehong Chen, Shilei Chen, Fengchao Wang, Song Wang, Junping Wang
Journal: Leukemia (2023)
Association between antenatal diagnosis of late fetal growth restriction and educational outcomes in mid-childhood: A UK prospective cohort study with long-term data linkage study
Authors: Laurentya Olga, Ulla Sovio, Hilary Wong, Gordon Smith, Catherine Aiken
Journal: PLoS Medicine (2023)

Background Fetal growth restriction (FGR) is associated with a suboptimal intrauterine environment, which may adversely impact fetal neurodevelopment. However, analysing neurodevelopmental outcomes by observed birthweight fails to differentiate between true FGR and constitutionally small infants and cannot account for iatrogenic intervention. This study aimed to determine the relationship between antenatal FGR and mid-childhood (age 5 to 7 years) educational outcomes. Methods and findings The Pregnancy Outcome Prediction Study (2008–2012) was a prospective birth cohort conducted in a single maternity hospital in Cambridge, United Kingdom. Clinicians were blinded to the antenatal diagnosis of FGR. FGR was defined as estimated fetal weight (EFW) &lt;10th percentile at approximately 36 weeks of gestation, plus one or more indicators of placental dysfunction, including ultrasonic markers and maternal serum levels of placental biomarkers. A total of 2,754 children delivered at term were divided into 4 groups: FGR, appropriate-for-gestational age (AGA) with markers of placental dysfunction, healthy small-for-gestational age (SGA), and healthy AGA (referent). Educational outcomes (assessed at 5 to 7 years using UK national standards) were assessed with respect to FGR status using regression models adjusted for relevant covariates, including maternal, pregnancy, and socioeconomic factors. Compared to healthy AGA ( N = 1,429), children with FGR ( N = 250) were at higher risk of “below national standard” educational performance at 6 years (18% versus 11%; aOR 1.68; 95% CI 1.12 to 2.48, p = 0.01). By age 7, children with FGR were more likely to perform below standard in reading (21% versus 15%; aOR 1.46; 95% CI 0.99 to 2.13, p = 0.05), writing (28% versus 23%; aOR 1.46; 95% CI 1.02 to 2.07, p = 0.04), and mathematics (24% versus 16%; aOR 1.49; 95% CI 1.02 to 2.15, p = 0.03). This was consistent whether FGR was defined by ultrasound or biochemical markers. The educational attainment of healthy SGA children ( N = 126) was comparable to healthy AGA, although this comparison may be underpowered. Our study design relied on linkage of routinely collected educational data according to nationally standardised metrics; this design allowed a high percentage of eligible participants to be included in the analysis (75%) but excludes those children educated outside of government-funded schools in the UK. Our focus on pragmatic and validated measures of educational attainment does not exclude more subtle effects of the intrauterine environment on specific aspects of neurodevelopment. Conclusions Compared to children with normal fetal growth and no markers of placental dysfunction, FGR is associated with poorer educational attainment in mid-childhood.
Letter to the editor: Quality criteria for computational models predicting individual outcomes in CAR-T cell therapy
Authors: Anna M Mc Laughlin, Cassian Yee
Journal: Journal for ImmunoTherapy of Cancer (2023)

Chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of relapsed/refractory hematological malignancies. Using CAR-T cell therapy, a high percentage of patients respond initially, yet up to 60% of patients eventually relapse. Predictive and prognostic factors allowing to predict
Correction: Acute kidney injury in patients treated with immune checkpoint inhibitors
Journal: Journal for ImmunoTherapy of Cancer (2023)

Figure 2 has been updated, there was a calculation error in panels 2J and 2K.The authors had indicated that 56.2% of patients had pyuria, when it was in fact 57.8%.The definition of pyuria has been updated to be ≥10 WBCs per high power field from ≥5 WBCs per high power field since 10 is the cutoff used more often than 5 in the literature.Furthermore, 61.7% of patients had a urine protein-to-creatinine ratio ≥0.3 g/g, not 58.7%.
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)
Authors: Marwan Fakih, Wael Harb, Daruka Mahadevan, Hani Babiker, Jordan Berlin, Tom Lillie, David Krige, Jo Carter, Chris Cox, Minesh Patel, Lola Parfitt, Mark Powell, Lee Rosen
Journal: Journal for ImmunoTherapy of Cancer (2023)

Novel combination therapies to overcome anti-PD-1 resistance are required. Enadenotucirev, a tumor-selective blood stable adenoviral vector, has demonstrated a manageable safety profile and ability to increase tumor immune-cell infiltration in phase I studies in solid tumors.We conducted a phase I multicenter study of intravenous enadenotucirev plus nivolumab in patients with advanced/metastatic epithelial cancer not responding to standard therapy. Co-primary objectives were safety/tolerability and maximum tolerated dose and/or maximum feasible dose (MTD/MFD) of enadenotucirev plus nivolumab. Additional endpoints included response rate, cytokine responses, and anti-tumor immune responses.Overall, 51 heavily pre-treated patients were treated, 45/51 (88%) of whom had colorectal cancer (35/35 patients with information available were microsatellite instability-low/microsatellite stable) and 6/51 (12%) had squamous cell carcinoma of the head and neck. The MTD/MFD of enadenotucirev plus nivolumab was not reached, with the highest dose level tested (1×1012 vp day 1; 6×1012 vp days 3 and 5) shown to be tolerable. Overall, 31/51 (61%) patients experienced a grade 3-4 treatment-emergent adverse event (TEAE), most frequently anemia (12%), infusion-related reaction (8%), hyponatremia (6%), and large intestinal obstruction (6%). Seven (14%) patients experienced serious TEAEs related to enadenotucirev; the only serious TEAE related to enadenotucirev occurring in >1 patient was infusion-related reaction (n=2). Among the 47 patients included in efficacy analyses, median progression-free survival was 1.6 months, objective response rate was 2% (one partial response for 10 months), and 45% of patients achieved stable disease. Median overall survival was 16.0 months; 69% of patients were alive at 12 months. Persistent increases in Th1 and related cytokines (IFNγ, IL-12p70, IL-17A) were seen from ~day 15 in two patients, one of whom had a partial response. Among the 14 patients with matching pre-tumor and post-tumor biopsies, 12 had an increase in intra-tumoral CD8+ T-cell infiltration and 7 had increased markers of CD8 T-cell cytolytic activity.Intravenously dosed enadenotucirev plus nivolumab demonstrated manageable tolerability, an encouraging overall survival and induced immune cell infiltration and activation in patients with advanced/metastatic epithelial cancer. Studies of next-generation variants of enadenotucirev (T-SIGn vectors) designed to further re-program the tumor microenvironment by expressing immune-enhancer transgenes are ongoing.NCT02636036.
High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis
Authors: Jaeyun Jung, You Jeong Heo, Sehhoon Park
Journal: Journal for ImmunoTherapy of Cancer (2023)

Background Tumor mutation burden (TMB) is an important biomarker to predict response to anti-PD-L1 treatment across cancer types. TruSight Oncology 500 (TSO500) is currently used globally as a routine assay for TMB. Methods Between 2019 and 2021, 1744 patients with cancer received TSO500 assay as part of a real-world clinical practice at the Samsung Medical Center, and 426 received anti-PD-(L)1 treatment. Correlations between TMB and clinical outcomes of anti-PD-(L)1 were analyzed. Digital spatial profiling (DSP) was used to investigate the tumor immune environment’s influence on the treatment response to anti-PD-(L)1 in high TMB (TMB-H) patients (n=8). Results The incidence of TMB-H (≥10 mutations (mt)/megabase (Mb)) was 14.7% (n=257). Among TMB-H patients, the most common cancer type was colorectal cancer (n=108, 42.0%), followed by gastric cancer (GC; n=49, 19.1%), bladder cancer (n=21, 8.2%), cholangiocarcinoma (n=21, 8.2%), non-small cell lung cancer (n=17, 6.6%), melanoma (n=8, 3.1%), gallbladder cancer (GBC; n=7, 2.7%), and others (n=26, 10.1%). The response rate to anti-PD-(L)1 therapy was substantially higher in GC (71.4% vs 25.8%), GBC (50.0% vs 12.5%), head and neck cancer (50.0% vs 11.1%), and melanoma (71.4% vs 50.7%) among TMB-H patients when compared with low TMB (TMB-L) (&lt;10 mt/Mb) patients with statistical significance. Additional analysis of patients with TMB ≥16 mt/Mb demonstrated prolonged survival after anti-PD-(L)1 therapy compared with patients with TMB-L (not reached vs 418 days, p=0.03). The benefit of TMB ≥16 mt/Mb was greater when combined with microsatellite status and PD-L1 expression profiles. Among the TMB-H patients, those who responded to anti-PD-L1 therapy had numerous active immune cells that infiltrated the tumor regions during the DSP analysis. Natural killer cells (p=0.04), cytotoxic T cells (p&lt;0.01), memory T cells (p&lt;0.01), naïve memory T cells (p&lt;0.01), and proteins related to T-cell proliferation (p&lt;0.01) were observed in a responder group compared with a non-responder group. In contrast, exhausted T-cell and M2 macrophage counts were increased in the non-responder group. Conclusions The overall incidence of TMB status was analyzed by the TSO500 assay, and TMB-H was observed in 14.7% of the pan-cancer population. In a real-world setting, TMB-H identified by a target sequencing panel seemed to predict response to anti-PD-(L)1 therapy, especially in patients with a higher proportion of immune cells enriched in the tumor region.
YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6
Authors: Saisai Chen, Kai Lu, Yue Hou, Zonghao You, Chuanjun Shu, Xiaoying Wei, Tiange Wu, Naipeng Shi, Guangyuan Zhang, Jianping Wu, Shuqiu Chen, Lihua Zhang, Wenchao Li, Dingxiao Zhang, Shenghong Ju, Ming Chen, Bin Xu
Journal: Journal for ImmunoTherapy of Cancer (2023)

Background Tumor-associated macrophages are mainly polarized into the M2 phenotype, remodeling the tumor microenvironment and promoting tumor progression by secreting various cytokines. Methods Tissue microarray consisting of prostate cancer (PCa), normal prostate, and lymph node metastatic samples from patients with PCa were stained with Yin Yang 1 (YY1) and CD163. Transgenic mice overexpressing YY1 were constructed to observe PCa tumorigenesis. Furthermore, in vivo and in vitro experiments, including CRISPR-Cas9 knock-out, RNA sequencing, chromatin immunoprecipitation (ChIP) sequencing, and liquid–liquid phase separation (LLPS) assays, were performed to investigate the role and mechanism of YY1 in M2 macrophages and PCa tumor microenvironment. Results YY1 was highly expressed in M2 macrophages in PCa and was associated with poorer clinical outcomes. The proportion of tumor-infiltrated M2 macrophages increased in transgenic mice overexpressing YY1. In contrast, the proliferation and activity of anti-tumoral T lymphocytes were suppressed. Treatment targeting YY1 on M2 macrophages using an M2-targeting peptide-modified liposome carrier suppressed PCa cell lung metastasis and generated synergistic anti-tumoral effects with PD-1 blockade. IL-4/STAT6 pathway regulated YY1, and YY1 increased the macrophage-induced PCa progression by upregulating IL-6. Furthermore, by conducting H3K27ac-ChIP-seq in M2 macrophages and THP-1, we found that thousands of enhancers were gained during M2 macrophage polarization, and these M2-specific enhancers were enriched in YY1 ChIP-seq signals. In addition, an M2-specific IL-6 enhancer upregulated IL-6 expression through long-range chromatin interaction with IL-6 promoter in M2 macrophages. During M2 macrophage polarization, YY1 formed an LLPS, in which p300, p65, and CEBPB acted as transcriptional cofactors. Conclusions Phase separation of the YY1 complex in M2 macrophages upregulated IL-6 by promoting IL-6 enhancer–promoter interactions, thereby increasing PCa progression.
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study
Authors: Adèle de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, Jean-Baptiste Mear, Stéphane Dalle, Michel d'Incan, Saskia Ingen-Housz-Oro, Corentin Orvain, Julie Abraham, Olivier Dereure, Amandine Charbonnier, Jérôme Cornillon, Christine Longvert, Stéphane Barete, Serge Boulinguez, Ewa Wierzbicka-Hainaut, François Aubin, Marie-Thérèse Rubio, Marc Bernard, Aline Schmidt-Tanguy, Roch Houot, Anne Pham-Ledard, David Michonneau, Pauline Brice, Hélène Labussière-Wallet, Jean-David Bouaziz, Florent Grange, Hélène Moins-Teisserenc, Katayoun Jondeau, Laurence Michel, Samia Mourah, Maxime Battistella, Etienne Daguindau, Michael Loschi, Alexandra Picard, Nathalie Franck, Natacha Maillard, Anne Huynh, Stéphanie Nguyen, Ambroise Marçais, Guillaume Chaby, Patrice Ceballos, Yannick Le Corre, Sébastien Maury, Jacques-Olivier Bay, Henri Adamski, Emmanuel Bachy, Edouard Forcade, Gérard Socié, Martine Bagot, Sylvie Chevret, Régis Peffault de Latour, Adèle de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, Jean-Baptiste Mear, Stéphane Dalle, Michel d'Incan, Saskia Ingen-Housz-Oro, Corentin Orvain, Julie Abraham, Olivier Dereure, Amandine Charbonnier, Jérôme Cornillon, Christine Longvert, Stéphane Barete, Serge Boulinguez, Ewa Wierzbicka-Hainaut, François Aubin, Marie-Thérèse Rubio, Marc Bernard, Aline Schmidt-Tanguy, Roch Houot, Anne Pham-Ledard, David Michonneau, Pauline Brice, Hélène Labussière-Wallet, Jean-David Bouaziz, Florent Grange, Hélène Moins-Teisserenc, Katayoun Jondeau, Laurence Michel, Samia Mourah, Maxime Battistella, Etienne Daguindau, Michael Loschi, Alexandra Picard, Nathalie Franck, Natacha Maillard, Anne Huynh, Stéphanie Nguyen, Ambroise Marçais, Guillaume Chaby, Patrice Ceballos, Yannick Le Corre, Sébastien Maury, Jacques-Olivier Bay, Henri Adamski, Emmanuel Bachy, Edouard Forcade, Gérard Socié, Martine Bagot, Sylvie Chevret, Régis Peffault de Latour, Adèle de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, Stéphane Dalle, Michel d'Incan, Saskia Ingen-Housz-Oro, Olivier Dereure, Christine Longvert, Stéphane Barete, Serge Boulinguez, Ewa Wierzbicka-Hainaut, François Aubin, Anne Pham-Ledard, Florent Grange, Alexandra Picard, Nathalie Franck, Guillaume Chaby, Yannick Le Corre, Henri Adamski, Maxime Battistella, Martine Bagot, Jean-Baptiste Mear, Corentin Orvain, Julie Abraham, Amandine Charbonnier, Jérôme Cornillon, Marie-Thérèse Rubio, Marc Bernard, Aline Schmidt-Tanguy, Roch Houot, David Michonneau, Pauline Brice, Hélène Labussière-Wallet, Katayoun Jondeau, Etienne Daguindau, Michael Loschi, Natacha Maillard, Anne Huynh, Stéphanie Nguyen, Ambroise Marçais, Patrice Ceballos, Régis Peffault de Latour, Emmanuel Bachy, Edouard Forcade, Gérard Socié, Sébastien Maury, Jacques-Olivier Bay
Journal: The Lancet (2023)
Advancing non-destructive analysis of 3D printed medicines
Authors: Anna Kirstine Jørgensen, Jun Jie Ong, Maryam Parhizkar, Alvaro Goyanes, Abdul W. Basit
Journal: Trends in Pharmacological Sciences (2023)

Pharmaceutical 3D printing (3DP) has attracted significant interest over the past decade for its ability to produce personalised medicines on demand. However, current quality control (QC) requirements for traditional large-scale pharmaceutical manufacturing are irreconcilable with the production offered by 3DP. The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) have recently published documents supporting the implementation of 3DP for point-of-care (PoC) manufacturing along with regulatory hurdles. The importance of process analytical technology (PAT) and non-destructive analytical tools in translating pharmaceutical 3DP has experienced a surge in recognition. This review seeks to highlight the most recent research on non-destructive pharmaceutical 3DP analysis, while also proposing plausible QC systems that complement the pharmaceutical 3DP workflow. In closing, outstanding challenges in integrating these analytical tools into pharmaceutical 3DP workflows are discussed.
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)
Authors: James D Chalmers, Eva Polverino, Megan L Crichton, Felix C Ringshausen, Anthony De Soyza, Montserrat Vendrell, Pierre Régis Burgel, Charles S Haworth, Michael R Loebinger, Katerina Dimakou, Marlene Murris, Robert Wilson, Adam T Hill, Rosario Menendez, Antoni Torres, Tobias Welte, Francesco Blasi, Josje Altenburg, Michal Shteinberg, Wim Boersma, J Stuart Elborn, Pieter C Goeminne, Stefano Aliberti
Journal: The Lancet Respiratory Medicine (2023)

Bronchiectasis is a heterogeneous, neglected disease with few multicentre studies exploring the causes, severity, microbiology, and treatment of the disease across Europe. This aim of this study was to describe the clinical characteristics of bronchiectasis and compare between different European countries.
Strengthening the maternal and child health responses to Ebola outbreaks in Uganda
Authors: Melissa Chowdhury, Joseph Ouma, Eve Nakabembe, Juliet Mwanga-Amumpaire, Bruce Kirenga, Henry Kyobe Bosa, Misaki Wayengera, Kirsty Le Doare, Musa Sekikubo
Journal: The Lancet Infectious Diseases (2023)
Mitochondrial cannabinoid receptors gate corticosterone impact on novel object recognition
Authors: Urszula Skupio, Julia Welte, Roman Serrat, Abel Eraso-Pichot, Francisca Julio-Kalajzić, Doriane Gisquet, Astrid Cannich, Sebastien Delcasso, Isabelle Matias, Unai B. Fundazuri, Sandrine Pouvreau, Antonio C. Pagano Zottola, Gianluca Lavanco, Filippo Drago, Inigo Ruiz de Azua, Beat Lutz, Luigi Bellocchio, Arnau Busquets-Garcia, Francis Chaouloff, Giovanni Marsicano
Journal: Neuron (2023)
Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson’s disease
Authors: Matthew T. Rocco, Asad S. Akhter, Debra J. Ehrlich, Gretchen C. Scott, Codrin Lungu, Vikas Munjal, Anthony Aquino, Russell R. Lonser, Massimo S. Fiandaca, Mark Hallett, John D. Heiss, Krystof S. Bankiewicz
Journal: Molecular Therapy (2023)

(Molecular Therapy, 30, 3632–3638; December 2022) In the originally published version of this article, volumes that were in microliters (μL) were mistakenly written as milliliters (mL). This incorrect abbreviation of units occurred during copyediting and was not present in the submitted article. All instances of this error have been changed in the article online, and Cell Press apologizes for any confusion this may have caused. Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson’s diseaseRocco et al.Molecular TherapyAugust 10, 2022In BriefThe study examined participants with advanced Parkinson’s disease, serially scanned up to 5 years after co-infusions of AAV-GDNF (glial cell line-derived neurotrophic factor) and gadoteridol, via convection-enhanced delivery with real-time intraoperative MRI. The results indicate no evidence of parenchymal toxicity evaluated in each MRI study at each time point. Full-Text PDF
Management of adult generalized pustular psoriasis using biologics: A systematic review
Authors: Abrahim Abduelmula, Brian D. Rankin, Siddhartha Sood, Jorge R. Georgakopoulos, Asfandyar Mufti, Ronald Vender, Jensen Yeung, Vimal H. Prajapati
Journal: Journal of the American Academy of Dermatology (2023)
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from the Collaborative Islet Transplant Registry
Authors: Mikaël Chetboun, Elodie Drumez, Cassandra Ballou, Mehdi Maanaoui, Elizabeth Payne, Franca Barton, Julie Kerr-Conte, Marie-Christine Vantyghem, Lorenzo Piemonti, Michael R Rickels, Julien Labreuche, François Pattou, R Alejandro, M Aull, M Bellin, T Berney, D Borja-Cacho, K Brayman, E Cagliero, R Caiazzo, M Cattral, T Coates, K Danielson, F Defrance, E De Koning, C Desai, N Desai, A O Gaber, V Gmyr, P Gores, J A Goss, P Gottllieb, C Greenbaum, M Hardy, D Harlan, B Hering, F Kandeel, D Kaufman, T Kay, B Keymeulen, K Khan, Y Kudva, C Larsen, K Le Mapihan, G Levy, M Levy, T Loudovaris, T Lundgren, P Maffi, J Markmann, W H Marks, A Naji, P O'Connell, J Oberholzer, J Odorico, N Onaca, F Pattou, L Piemonti, D Pipeleers, A Posselt, A Rajab, V Raverdy, M R Rickels, C Ricordi, A A Rossini, F Saudek, B Schrope, A Secchi, P Senior, A M J Shapiro, J Shaw, P Stock, D Thomas, M J Thompson, M C Vantyghem, L Vargas, H Wang, A Wiseman, P Witkowski, K Yoon
Journal: The Lancet Diabetes & Endocrinology (2023)
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018–2021
Authors: Yu-Lin Lee, Po-Ren Hsueh
Journal: Journal of Infection (2023)